TNGXTango Therapeutics Inc

$29.03
$2.88
(9.13%)
Today
Closed $28.68
$0.35
(1.22%)
After Hours
Updated: 06:30 PM EDT
Reported EarningsMay 13
Mkt Cap$4.57B
Vol9.85M
News
all
press releases
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Zacks
News Placeholder
More News
News Placeholder
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today
AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.read more...
Benzinga
News Placeholder
The Hottest Stocks Traders Are Chasing into the Closing Bell
As traders head into the final stretch of today's session, investor attention remains focused on a diverse group of emerging growth companies. $NTHI, $TNGX, $ABAT, $OCC, $INHD, $NPT, $BYAH, $GLXY, $ZVRA, $ASTI
24-7 Market News
News Placeholder
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer.
Stocktwits
News Placeholder
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and GENI.read more...
Benzinga
News Placeholder
FDA Milestones Fueling Expansion
The biotechnology sector delivered several notable developments. $TNGX, $NTHI, $AIM, $AZN, $NRIX, $NYXH
24-7 Market News
News Placeholder
Why Is Tango Therapeutics Stock Soaring Monday?
Tango Therapeutics reports 90% 6-month PFS in pancreatic cancer trial. Read about the vopimetostat combo driving TNGX stock up.read more...
Benzinga
News Placeholder
Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement
Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement...
Yahoo! Finance: News
News Placeholder
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Zacks
News Placeholder
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Key PointsRTW Investments added 11,809,392 shares of Tango Therapeutics last quarter; the estimated transaction value was $164.37 million based on average prices during the quarter...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.